𝗪𝗼𝗿𝗹𝗱 𝗧𝗵𝗿𝗼𝗺𝗯𝗼𝘀𝗶𝘀 𝗗𝗮𝘆 — 𝟭𝟯 𝗢𝗰𝘁𝗼𝗯𝗲𝗿 𝟮𝟬𝟮𝟱: "𝗙𝗿𝗼𝗺 𝗛𝗲𝗮𝗱 𝘁𝗼 𝗧𝗼𝗲, 𝗧𝗮𝗸𝗲 𝗖𝗼𝗻𝘁𝗿𝗼𝗹: 𝗣𝗿𝗲𝘃𝗲𝗻𝘁 𝗧𝗵𝗿𝗼𝗺𝗯𝗼𝘀𝗶𝘀, 𝗣𝗿𝗼𝘁𝗲𝗰𝘁 𝗬𝗼𝘂𝗿 𝗛𝗲𝗮𝗹𝘁𝗵."

Thrombosis (blood clots) can block veins or arteries and lead to deep vein thrombosis, pulmonary embolism, heart attack, or stroke. Many risk factors are common and modifiable — prolonged immobility, recent surgery, cancer, hormone therapy, obesity, smoking, and unmanaged chronic diseases — so early recognition (leg swelling/pain, sudden shortness of breath, chest pain, sudden weakness or speech changes) and timely medical assessment save lives.

Take simple steps to reduce risk: stay active and hydrate during long travel, maintain a healthy weight, quit smoking, control diabetes and heart disease, use compression stockings when advised, and follow anticoagulant instructions carefully. Share this message so more people know the signs and preventive actions — from head to toe, take control.

#WorldThrombosisDay #ThrombosisAwareness #PreventVTE #DVT #PulmonaryEmbolism #BloodClots #HeartHealth #StrokePrevention #TravelSafely #Anticoagulation #KnowTheSigns #SCABPharmacy

Iniciar tratamiento con #anticoagulante oral en los primeros 4 días después de un #EVC #isquémico en un paciente con #FibrilaciónAuricular es seguro, y beneficia más al paciente que iniciarlo después (5-14 días).

#OPTIMAS #CATALYST #Ischemic #Stroke #Anticoagulation #AtrialFibrillation

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)02197-4/fulltext

#Anticoagulation and venous thromboembolism in patients aged 90 years and older

In very old patients, you may need different management for the same condition according to the initial clinical presentation.

In other words, one-fits-all does not work...

#Geriatrics #Aging #Care #Medical

https://agsjournals.onlinelibrary.wiley.com/doi/abs/10.1111/jgs.18626

Use of #anticoagulation treatments for hospitalized #COVID patients decreased after #omicron. Patients more likely to get anticoagulation treatment included being older, being Black, obesity, length of hospital stay, being on a ventilator, being high risk, and being unvaccinated.

#TWiVTLDR 9/

En pacientes con #FibrilaciónAuricular que sufren un #EVC, la evidencia favorece el inicio temprano de #anticoagulación (en los primeros 2 días) sobre el retraso de la misma.

#Stroke #AF #AtrialFibrillation #anticoagulation

https://www.nejm.org/doi/full/10.1056/NEJMoa2303048?query=featured_home

Should we delay #anticoagulation of #stroke in all patient because a frequentist analysis said so? Is this the way the clinician see things when making its decision?

#NEJM #NeuroCriticalCare

https://www.nejm.org/doi/full/10.1056/NEJMoa2303048

High-dose prophylactic #anticoagulation is (was?) affective to reduce the occurence of #thrombosis without impacting outcomes in #Covid hypoxemic failure

https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2802821

#JAMAInternalMedicine #FOAMcc #CriticalCare

Effects of Anticoagulation Dosage in Patients with Hypoxemic COVID-19 Pneumonia

This randomized clinical trial compares the effects of high-dose, standard-dose, and therapeutic anticoagulation on mortality and/or disease duration among patients with hypoxemic COVID-19 pneumonia in 23 hospitals in France.

#FREEDOM #COVID #Anticoagulation Strategy Randomized Trial:

High-dose subcutaneous enoxaparin or oral apixaban – to inhibit thrombosis and progression of disease – can reduce deaths by 30%, intubations by 25% in hospitalized patients with pulmonary involvement but not yet in the #ICU, when compared to the standard treatment (low-dose anticoagulation).

https://medicalxpress.com/news/2023-03-high-dose-anticoagulation-intubations-survival-hospitalized.html

#SARSCoV2 @novid

High-dose anticoagulation can reduce intubations and improve survival for hospitalized COVID-19 patients

High-dose anticoagulation can reduce deaths by 30 percent and intubations by 25 percent in hospitalized COVID-19 patients who are not critically ill when compared to the standard treatment, which is low-dose anticoagulation. These are the significant findings from the large-scale international "FREEDOM" trial, led by Valentin Fuster, MD, Ph.D., President of Mount Sinai Heart and Physician-in-Chief of The Mount Sinai Hospital, and General Director of the Spanish National Center for Cardiovascular Research (CNIC).

Man lernt nie aus. Zum wiederholten Male habe ich heute die große und bisher völlig unbekannte Hauptschlagader im linken kleinen Finger getroffen. Trotz massiven Blutverlustes, konnte ein hervorragendes Ergebnis ermittelt werden. Ein wahrlich perfekter #INR.

#anticoagulation